Podcasts about Status epilepticus

Emergency treatment may be necessary after a person's first seizure or at the onset of abnormal acute repetitive (cluster) seizures; it is required for status epilepticus. Treatment for these emergencies is dictated by myriad clinical factors and informed by published guidance as well as emerging research.   In this episode, Lyell K. Jones, MD, FAAN, speaks with David G. Vossler, MD, FAAN, FACNS, FAES, author of the article “First Seizures, Acute Repetitive Seizures, and Status Epilepticus,” in the Continuum® February 2025 Epilepsy issue. Dr. Jones is the editor-in-chief of Continuum: Lifelong Learning in Neurology® and is a professor of neurology at Mayo Clinic in Rochester, Minnesota. Dr. Vossler a clinical professor of neurology at the University of Washington School of Medicine in Seattle, Washington. Additional Resources Read the article: First Seizures, Acute Repetitive Seizures, and Status Epilepticus Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @LyellJ  Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, which features conversations with Continuum's guest editors and authors who are the leading experts in their fields. Subscribers to the Continuum journal can read the full article or listen to verbatim recordings of the article and have access to exclusive interviews not featured on the podcast. Please visit the link in the episode notes for more information on the article, subscribing to the journal, and how to get CME. Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum: Lifelong Learning in Neurology. Today, I'm interviewing Dr Dave Vossler, who has recently authored an article on emergent seizure management, taking care of patients with the first seizure, acute repetitive seizures, and status epilepticus, which is an article in our latest issue of Continuum covering all topics related to epilepsy. Dr Vossler is a neurologist at the University of Washington, where he's a clinical professor of neurology and has an active clinical and research practice in epileptology. Dr Vossler, welcome. Thank you for joining us today. Why don't you introduce yourself to our listeners? Dr Vossler: Thank you very much for the introduction, Lyell. It's a pleasure to speak with you on this podcast, and I hope to go over a lot of important new information in the management of seizure emergencies. As you said, I'm a clinical professor in neurology at University of Washington, been in medicine for many decades now and have published and done research in this area. So, I'm anxious to give you not only my academic experience, but also talk about my own management of patients with status epilepticus over the last four decades. Dr Jones: Yeah, that's fantastic. And I always appreciate hearing from experienced clinicians, and I think our readers and our listeners do appreciate that voice of clinical expertise. And I'll tell you this is a topic, you know, as a neurologist who doesn't see many patients with acute seizure emergencies in my own practice, I think this is a topic that gives many clinicians, including neurologists, some anxiety. Your article, Dr Vossler, is really chock-full of helpful and clinically relevant considerations in the acute management of seizures. So, you now have the full attention of a huge audience of mostly neurologists. What's the one most important practice change that you would like to see in the care of patients with either first or acute prolonged seizures? Dr Vossler: Without a doubt, the most important clinical takeaway with regard to the status epilepticus---and for status epilepticus, many, many clinical trials, research trials have been done over the last couple decades and they all consistently show the same thing, that by and large most patients who have status epilepticus are underdosed and undertreated and treated too slowly in the initial stages of the status epilepticus. And it's important to use full bolus dosages of benzodiazepines to prevent mortality, morbidity, and later disability of these patients. To prevent the respiratory depression, many physicians are afraid to use higher doses of benzodiazepines, even guideline-recommended doses of benzodiazepines for fear of respiratory depression. But it's actually counterintuitive. It turns out that most cases of respiratory depression are due to inadequate doses and due to the status epilepticus itself. We know there's greater mortality, we know there's greater morbidity and we know that there's greater need for higher dose, subsequent, anti-seizure medications, prolonged status, if we don't use the proper doses. So, we'll kind of go over that a little bit, but that is the one clinical takeaway that I really would like our listeners to have. Dr Jones: Let's follow that thread a little bit. Dave, I know obviously we will speak in hypotheticals here. We're not going to talk about actual patients, but I think we've all been in the clinical situation where you have a patient who comes into the emergency room usually who's actively seizing, unknown history, don't know much about the patient, don't know much about the circumstances of the onset of the seizure. But we now have a patient with prolonged convulsive seizures. How do we walk through that? What are the first steps in the management of that patient? Dr Vossler: Yeah, well, I'll try to be brief for the purposes of the podcast. We do, of course, go through all of that in detail in the Continuum article, which hopefully everybody will look at very carefully. Really in the first table, the very first table of the article, I go through the recommended guideline for the American Epilepsy Society on the management of what we call established status epilepticus. The scenario you're talking about is just exactly that: established status epilepticus. It's not sort of evolving or developing status. We're okay they're having a few seizures and we're kind of getting there. No, this patient is now having evidence of convulsive seizure activity and it's continuing or it's repeated seizures without recovery. And so, the first phase is definitely a benzodiazepine and then the second phase is then a longer-acting bolus of a drug like phosphenotoine, valproic acid or levetiracetam. I could get into the details about dosing of the benzodiazepines, but maybe I'll let you guide me on whether we wanted to get into that kind of detail right at the outset. It's going to be a little bit different. For children, its weight-based dosing, but for adults, whether you use lorazepam or you use diazepam or you use midazolam, the doses are a little bit different. But they are standardized, and gets back to this point that I made earlier, we're acting too slow. We're not getting these patients quick enough, for various reasons, and the doses that are most commonly used are below what the guidelines call for. Dr Jones: That's great to know, and I think it's fine for the details to refer our listeners to the article because there are great details in there about a step-by-step approach to the established status epilepticus. The nomenclature and the definitions have evolved, haven't they, Dr Vossler, over time? Refractory status epilepticus, new-onset refractory status epilepticus, super refractory status epilepticus. Tell us about those entities, how they're distinguished and how you approach those. Dr Vossler: That's an important thing to kind of go over. They- in 2015, the International League Against Epilepsy, ILAE, which is, again, our international organization that guides our understanding of all kinds of things epileptic in nature around the world. In 2015 they put out a definition of status epilepticus, but it used to be that patients had thirty minutes of continuous seizure activity or repetitive obvious motor seizures with impairment of awareness and they don't recover impairment between these seizures. And that goes on for thirty minutes. That was the old definition of status epilepticus. Now, the operational definition is five minutes. And I think that's key to understand that, after five minutes of this kind of overt seizure activity, you need to intervene. And that's what's called T1 in the 2015 guideline, the international guideline. There are a bunch of different axes in the classification of status that talk about semiology, etiology, EEG patterns, and what age group you're talking about. We won't really get into those in the Continuum article because that's really more detailed than a clinician really should be. Needing to think about the stages, what we call the stages of status epilepticus that you mentioned and I alluded to earlier are important. And that is sort of new nomenclature, and I think probably general neurologists and most emergency room physicians aren't familiar with those. So, it just briefly goes through those. Developing status epilepticus is where you're starting- the patient's starting to have more frequent seizures, and it's heading essentially in the wrong direction, if you will. Established status epilepticus, as I mentioned, is, you know, this seizure act, convulsive or major, major outward overt seizure activity lasting five minutes or more, at which time therapy needs to begin. Again, getting back to my point, what doesn't happen often enough is we're not- we're intervening too late. Third is refractory status epilepticus, which refers to status epilepticus which continues despite adequate doses of an initial benzodiazepine given parenterally followed by a full loading dose of a single non-sedating anti-seizure medicine, which today includes phosphenotoine IV valproic acid or IV levetiracetam. In the United States, and increasingly around the world, people really are using levetiracetam. First, it has some advantages. There's now proof from a class one NIH-funded trial. We know that these three drugs are equivalent at the full doses that I go over in the article. You have your kind of dealer's choice on those. Phenobarbital, which we used to use and I used as a resident as long as forty years ago, is really a second choice drug because of its sedating and other side effects. But around the world in resource-poor countries phenobarbital can be used and, in a pinch, certainly is an appropriate drug. And then finally, you mentioned super refractory status epilepticus and that's status that's persisting for more than twenty four hours. Now, despite initial benzo and non-sedating anti-seizure medicine, but also lasting more than twenty four hours while receiving an intravenous infusional sedating, anesthetizing anti-seizure medicine like ketamine, propofol, pentobarbital or midazolam drips. Dr Jones: So, it sounds like the definitions have evolved in a way that improves the outcomes, right? To do earlier identification of status epilepticus and more aggressive management, I think that's a great takeaway. If we move all the way to the other end of the spectrum, let's move to the ambulatory setting and we have a patient who comes in and they've had one seizure, they're an adult; one seizure, the first seizure. The key question is, how do we anticipate the risk of future seizures? But walk us through how you talk to that patient, how you evaluate that patient to decide if and when to start anti-seizure medicines. Dr Vossler: Well, it depends a little bit if it's an adult or a child, but the decision making process and the data behind it is pretty robust now. And the decision making process is pretty similar for adults and children, with some differences which I can talk about. First of all, first seizures. I think it's really important to stress that there's been so much research in this area. I'd like to get a cross point that they're not as innocuous as I think many general neurologists might suspect. We know that there is a two- to threefold increased risk of death in children and adults following a first seizure. Moreover, the risk of a second seizure, both in kids and adults, is about 36% two years after that first seizure. It's about 46% five years after that first seizure. It's really pretty substantial. The risk of a second seizure is increased twofold. It doubled in the presence of any kind of a history of prior brain insults that could result in seizures. Could be infections, it could be a prior stroke, it could be prior significant brain trauma. It's also doubled in the presence of an EEG, which shows epileptiform discharges like spikes and sharp waves---and not just a sort of borderline things like sharply contoured rhythmic Theta activity. That's really not what we're talking about. We're talking about overt epileptiform discharges. It's doubled in the presence of lesion that can be seen on imaging studies, and it's doubled in the presence of seizures if that first seizure occurs during sleep. So, we have a number of things that double the risks, above the risk of a second seizure, above that 36% at two years and 46% at five years that I spoke about. And so those things need to be considered when you're counseling a patient about that. Should you be on an anti-seizure medicine after that first seizure? Specifically, to the point of anti-seizure medications, the guideline that was done, the 2015 guideline that was done by the American Academy of Neurology for adults, and the 2003 guideline was actually a practice parameter that was done by the Academy and the American Epilepsy Society for children, are really kind of out of date. They talk about the adverse effects of anti-seizure medications, but when you look back at the studies that were included in developing that practice parameter for kids and guidelines for adults, they are the old drugs: carbamazepine, phenytoin, phenobarbital and valproate. Well, I don't think I need to tell this audience, this well-educated audience, that we don't use those drugs anymore. We are using more modern anti-seizure medicines that have been developed since 1995; things like lamotrigine, levetiracetam, and lecosamide. Those three in particular have very low adverse events. So, the guideline that the Academy, American Academy Neurology and American Epilepsy Society put together for kids and for adults talks about this high adverse event profile. And so, you need to take a look at the risks that I talked about of a seizure recurrence and balance that against adverse effects. But I'm here to tell you that the newer anti-seizure medicines---and by newer I'm talking in the last thirty years since lamotrigine was approved in 1995---these drugs have much better side effect profiles. And I think all epileptologists would agree with that. They're not necessarily more effective, but they are better tolerated. That makes the discussion of the risk of a second seizure, the risk of mortality versus side effects of drugs, it really pushes the risk category higher on the first side and not on the side of drugs. We know that if you take an anti-seizure medicine, you reduce your risk of a second seizure by half. Now, that's not sustained over five years, but over the first two years, you've reduced it by half. In a person who's driving, needs to get to work, has to take the kids to school, whatever, most of my patients are like, yeah, okay, sign me up. These drugs are really pretty well tolerated. There's a substantial risk of a second seizure. So, I'll do that. In a kid,  a child that's, you know, not driving yet, that might be a different discussion. And the parents might say, well, I'd rather not have my son exposed, my daughter exposed to this. They're trying to go to school. They're trying to learn. We don't want to hinder that. We'll wait for a second seizure and then if they have a second seizure, which by the way is, you know, one of the definitions of epilepsy, well then they have epilepsy, then they probably will need to go on the seizure medication. Dr Jones: Great summary, Dr Vossler, and it is worth our audience being aware that the evidence has evolved alongside the improvement in the adverse effect profile. And sounds like your threshold is a little lower to treat then maybe it would have been some time ago, right? Dr Vossler: I would say that's exactly correct in my opinion. Particularly for adults, absolutely. Dr Jones: That's fantastic, Dr Vossler. I imagine there are a lot of aspects of caring for these patients that are challenging, and I imagine many scenarios are actually pretty rewarding. What do you find the most rewarding aspect of caring for patients with acute seizure management? Dr Vossler: Yes, I mean, that is really true. I would say that the most challenging things are treating refractory status epilepticus, but worse yet, new onset refractory status epilepticus and the super refractory status epilepticus, which I talk extensively about or write extensively about in the article and provide a lot of guidance on. Really, those conditions are so challenging because they can go on for such a long time. Patients are hospitalized for a long time. A lot of really good clinical guidance doesn't exist yet. There is a tremendous amount of research in that area which I find exciting, and really there's an amazing amount of international research on that, I think most of our audience probably is unaware of. And certainly, with those conditions, there is a high risk of later disability and mortality. We go through all of that in the article. The rewards really come from helping these people. When someone was super refractory status and it were non- sorry, new onset refractory status epilepticus, has been in the hospital for thirty days, it gets really hard for everybody; the family, the patient. And for us, it wears on us. Yet when they walk out the door, and I've had these people come back to the epilepsy clinic and see me later. We're managing their anti-seizure medications. They've survived. The NORSE patients often have substantial disability. They have cognitive and memory and even some psychiatric disability. But yet we can help them. It's not just management in the hospital, but it's getting to know these people, and I take them from the hospital and see them in my clinic and manage them long-term. I get a lot of great satisfaction out of that. We're hoping to do even better, stop patients' status early and get them to recover with no sequelae. Dr Jones: What a great visual, seeing those patients who have a devastating problem and they come back to clinic and you get the full circle. And what a great place to end. Dr Vossler, thank you so much for joining us, and thank you for such a thorough and fascinating discussion on the importance of understanding and managing patients with the first seizure, acute repetitive seizures, and status epilepticus. Dr Vossler: Thank you very much, Lyell. Dr Jones: Again, we've been speaking with Dr Dave Vossler, author of an article on emergent seizure management, first seizures, acute repetitive seizures and status epilepticus in Continuum's most recent issue on epilepsy. Please check it out, and thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

In this second part of our three-part series on emergency seizures, we discuss status epilepticus. This is a life-threatening emergency that we need to treat rapidly and often using a team approach. In this episode, we review what status epilepticus is, how common it is, what causes it, and what it can do to the body, along with initial management considerations.

Do you feel confident recognizing status epilepticus? When a seizure doesn't stop on its own, knowing the signs of this high-stakes emergency is the first step to preventing complications and even death. This episode breaks everything you need to know about status epilepticus — the warning signs, critical action steps, and the interventions that save lives.In this deep dive for Epilepsy Awareness Month, Sarah unpacks the role of nurses to take quick action and advocate for patients in status epilepticus. From what happens in the brain during prolonged seizures to proper use of benzodiazepines and anti-epileptic drugs, we get into the nitty gritty of managing this life-threatening condition. Topics discussed in this episode:Status epilepticus case studyDefining status epilepticus and its pathophysiologyHow to recognize the signs of status epilepticusIntervention tools and best practicesMedication use and managementPrevention and identification of underlying causesMentioned in this episode:Rapid Response and Rescue Intro CourseCONNECT

Dr Seana Molloy talking about Status Epileptics. This talk is part of the Paediatric Emergencies 2024 event. To get your CME certificate for watching the video please visit https://www.paediatricemergencies.com/conference/paediatric-emergencies-2024/ #PaediatricEmergencies #PaediatricEmergencies2024 #StatusEpileptics

Show notes at pharmacyjoe.com/episode969. In this episode, I'll discuss how a pharmacist can ensure the best possible outcomes for status epilepticus. The post 969: How a pharmacist can ensure the best possible outcomes for status epilepticus appeared first on Pharmacy Joe.

Show notes at pharmacyjoe.com/episode963. In this episode, I'll discuss what works best for toxin-related status epilepticus. The post 963: What Works Best for Toxin-Related Status Epilepticus? appeared first on Pharmacy Joe.

Status Epilepticus: Part II Special Guest: Jason Vilar, PharmD, BCCCP @TheBrainPharmD   03:40 – Definitions/Terminology 14:30 – Landmark status epilepticus (SE) literature 21:30 – Emergent ASM SE pharmacotherapy 26:00 – DDI management/TDM 33:55 – Refractory status epilepticus (RSE) treatment 48:15 – Medication safety considerations and weaning 58:00 – EEGs for PharmD's 68:10 – Inhaled anesthetics 74:30 – Studies on the horizon/take-home points   Reference List: https://pharmacytodose.com/wp-content/uploads/2024/08/status-epilepticus-part-ii-references.pdf   PharmacyToDose.Com @PharmacyToDose PharmacyToDose@Gmail.com Learn more about your ad choices. Visit megaphone.fm/adchoices

In the second episode of our MedPod series on seizure disorders, Brig (Dr) J Muthukrishnan is joined once again by Lt Col (Dr) Manish Bhartiya, an eminent neurologist from Command Hospital, Southern Command. This episode dives into the critical management of status epilepticus, a medical emergency requiring swift and effective intervention. Dr. Bhartiya also discusses the use of anti-seizure drugs in patients with epilepsy, providing insights into drug selection, dosing, and long-term management strategies.

Dr. Shuvro Roy and Dr. Mary Karalius discuss her paper "CSF Metagenomics and Host Transcriptomics of Cryptogenic New-onset Refractory Status Epilepticus." Show reference: https://www.aan.com/conferences-community/summer-conference/abstracts/

STATUS EPILEPTICUS (SE) is a life-threatening condition that affects 120 000 to 200 000 people annually in the United States.1 In its most severe form, refractory SE (RSE), continuous or repetitive seizures do not respond to first- and second-line anticonvulsant drug (ACD) therapy, Learn the last line therapeutic options for the treatment of RSE in the this episode of the pediatrics in review podcast 

AFR Case Studies 4 Year Old Status Epilepticus by Albuquerque Fire Rescue

In this episode, Sam Ashoo, MD and T.R. Eckler, MD interview Reuben J. Strayer, MD, author of the May 2024 Emergency Medicine Practice article, Current Concepts in Ketamine Therapy in the Emergency DepartmentDiving Into Ketamine Use in Emergency MedicineUnderstanding Ketamine: From Origins to Emergency UseExploring the Ketamine Brain ContinuumKetamine Dosing and Administration TechniquesCombining Ketamine with Neuroleptic MedicationsPractical Approaches to Ketamine for Pain ManagementInnovative Pain Management and Ketamine UseProcedural Sedation with Ketamine: Techniques and ConsiderationsAddressing Agitation and Sedation in Emergency SituationsNavigating Intubation Strategies: DSI and Ketamine-Only ApproachesKetamine's Role in Treating Asthma, Status Epilepticus, and Alcohol WithdrawalExploring Ketamine for Treatment-Resistant DepressionConcluding Remarks on Ketamine's Versatility in Emergency Medicine

Trial of the Week: ESETT Special Guest: Ashley McCormick, PharmD, BCPS, BCCCP   Ashley McCormick joins to discuss the April Trial of the Week “Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus” the ESETT study, published in NEJM in 2019. We set the scene by reviewing ASM PK/PD properties and discussing if there was a standard of care first-line treatment. Then we do a deep dive into the ESETT trial of the week. Did the 75kg dose cap influence results? How appropriate was the BZD dosing? How does this % of seizure cessation compare to other studies? Where did this dosing scheme come from? Trial fun facts, medication safety considerations, and much, much more. Reference list: https://pharmacytodose.files.wordpress.com/2024/04/esett-trial-of-the-week-references.pdf   PharmacyToDose.Com @PharmacyToDose PharmacyToDose@Gmail.com Learn more about your ad choices. Visit megaphone.fm/adchoices

Contributor: Aaron Lessen MD Educational Pearls: Lorazepam (Ativan) is dosed at 0.1 mg/kg up to a maximum of 4 mg in status epilepticus Some ED protocols only give 2 mg initially The maximum recommended dose of levetiracetam (Keppra) is 60 mg/kg or 4.5 g In one retrospective study, only 50% of patients received the correct dose of lorazepam For levetiracetam, it was only 35% of patients Underdosing leads to complications Higher rates of intubations More likely to progress to refractory status epilepticus References 1. Cetnarowski A, Cunningham B, Mullen C, Fowler M. Evaluation of intravenous lorazepam dosing strategies and the incidence of refractory status epilepticus. Epilepsy Res. 2023;190(November 2022):107067. doi:10.1016/j.eplepsyres.2022.107067 2. Sathe AG, Tillman H, Coles LD, et al. Underdosing of Benzodiazepines in Patients With Status Epilepticus Enrolled in Established Status Epilepticus Treatment Trial. Acad Emerg Med. 2019;26(8):940-943. doi:10.1111/acem.13811 Summarized by Jorge Chalit, OMSII | Edited by Meg Joyce & Jorge Chalit  

Dr Ben McNaughten talking about Status Epilepticus. This talk is part of the Paediatric Emergencies 2023 event. To get your CME certificate for listening to this podcast please visit https://www.paediatricemergencies.com/paediatric-emergencies-2023-feedback/ #PaediatricEmergencies #PaediatricEmergencies2023 #StatusEpilepticus

Today, Asif and Ali discuss the new Netflix docuseries ‘Wrestlers' (1:30). The guys discuss the director of the show, Greg Whiteley, and his other shows ‘Last Chance U' and ‘Cheer'. They then discuss the main characters in the show, including former wrestler Al Snow, talk radio celebrity Matt Jones and breakout star . They discuss their thoughts on the show and how the show is really about showmanship, devotion to craft and putting everything on the line for a dream.    Then, since a character in ‘Wrestlers' has what appears to be a seizure in one episode (mild spoiler), the guys then discuss seizures and pseudoseizures (24:40). Asif reviews the definition of seizures and epilepsy. He then goes over first aid for seizures and the dangers of brain injury with prolonged seizures (status epilepticus). In the show, the seizure appears to be precipitated by a stressful event. Asif explains that stress in and of itself does not really cause seizures, but it can be related to pseudoseizures aka non-epileptic events. These are a psychogenic type of disorder, also called conversion disorder or functional neurologic disorder. Asif talks about how these are often related to underlying stress or anxiety and how they can be related to a past history of psychological trauma. He describes how their appearance can be different from actual seizures and he also explains how a test (EEG) can help to differentiate these. Asif then goes over the treatment for this disorder.    The opinions expressed are those of the hosts, and do not reflect those of any other organizations. This podcast and website represents the opinions of the hosts. The content here should not be taken as medical advice. The content here is for entertainment and informational purposes only, and because each person is so unique, please consult your healthcare professional for any medical questions.    Music courtesy of Wataboi and 8er41 from Pixabay   Contact us at doctorvcomedian@gmail.com   Follow us on Social media: Twitter: @doctorvcomedian Instagram: doctorvcomedian   Show notes: Is Pro Wrestling Any Less 'Real' Than the Mayweather/McGregor Fight? Al Snow Doesn't Think So: https://www.menshealth.com/entertainment/a45156115/wrestlers-netflix-al-snow-interview/ ‘Wrestlers' Is Greg Whiteley's Latest Underdog Tale: https://www.nytimes.com/2023/09/13/arts/television/wrestlers-netflix-greg-whiteley.html The Hilarious Story of An Al Snow Toy Was Deemed "One of the Most Dangerous Toys in America": https://www.thesportster.com/wwe-hilarious-story-of-al-snow-toy-deemed-most-dangerous-toys-in-america/ Heritage Minutes: Wilder Penfield: https://www.youtube.com/watch?v=pUOG2g4hj8s A definition and classification of status epilepticus--Report of the ILAE Task Force on Classification of Status Epilepticus: https://pubmed.ncbi.nlm.nih.gov/26336950/ Functional/dissociative seizures: Review of its relationship with trauma, dissociation and the neurobiological underpinnings: https://www.sciencedirect.com/science/article/pii/S2772598722000526 Childhood trauma and psychogenic nonepileptic seizures: A review of findings with speculations on the underlying mechanisms: https://www.sciencedirect.com/science/article/pii/S1525505015005223 Psychogenic Nonepileptic Seizures: https://www.ncbi.nlm.nih.gov/books/NBK441871/ KY Medical Review Board Program: https://drive.ky.gov/Drivers/Pages/MRB.aspx

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Status Epilepticus ⁠⁠⁠from the Neurology section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets Linkedin: https://www.linkedin.com/company/medbullets

Hear of research into complex refractory & super refractory status epilepticus; treatments, outcomes, & how to improve each - with Christoph Beier. ------------------------------------------

Following their debate on approaches to early phase management of refractory status epilepticus (RSE), Salia Farrokh, PharmD is joined by Caroline Der Nigoghossian, Neurocritical Care PharmD, Renad Abu-Sawwa, PharmD, and Gabe Fontaine, PharmD to explore the benefits and harms/risks of early ketamine administration in refractory status epilepticus, as well as the emerging literature for the use of ketamine in pediatric neurocritical care.

Listen to the second episode of NCS's INSIGHTS series on Status Epilepticus (part 2 of 2) The INSIGHTS series is hosted by Casey Albin, MD and Salia Farrokh, PharmD, and covers different topics from Neurocritical Care ON CALL®, the only up-to-date, comprehensive resource to offer content exclusively dedicated to the practice of neurocritical care. Learn more about ON CALL®. This episode is sponsored by ceribell. Time is brain when it comes to seizures. Ceribell Point of Care EEG empowers the bedside team to detect or rule out seizure activity in minutes. To learn more, visit ceribell.com. The NCS Podcast is the official podcast of the Neurocritical Care Society.

Listen to the first episode of NCS's INSIGHTS series on Status Epilepticus Pt. 1.  The INSIGHTS series is hosted by Casey Albin, MD and Salia Farrokh, PharmD, and will cover different topics from Neurocritical Care ON CALL®, the only up-to-date, comprehensive resource to offer content exclusively dedicated to the practice of neurocritical care. To learn more about ON CALL®, click here.   This episode is sponsored by: Time is brain when it comes to seizures. Ceribell Point of Care EEG empowers the bedside team to detect or rule out seizure activity in minutes. To learn more, visit ceribell.com   The NCS Podcast is the official podcast of the Neurocritical Care Society. 

Show notes at pharmacyjoe.com/episode831. In this episode, I'll discuss the role for ketamine in status epilepticus. The post 831: What is the role for ketamine in refractory status epilepticus? appeared first on Pharmacy Joe.

Show notes at pharmacyjoe.com/episode831. In this episode, I ll discuss the role for ketamine in status epilepticus. The post 831: What is the role for ketamine in refractory status epilepticus? appeared first on Pharmacy Joe.

Listen as Dr. London Smith (.com) and his producer Cameron discuss Status Epilepticus with special guest Walter Whimsy (Adam Macias).  Sponsored by Caldera + Lab (use code "jockdoc" to get 20% off!). Not so boring! https://calderalab.com/pages/podcast-special-offer?show=Jock+Doc&utm_medium=podcast&utm_source=JocDoc https://www.patreon.com/join/jockdocpodcast Hosts: London Smith, Cameron Clark. Guest: Adam Macias. Produced by: Dylan Walker Created by: London Smith

Dr. Adam S. Greenblatt discusses which patients are affected by NORSE [New-Onset refractory status epilepticus]. This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.  

Dr. Adam S. Greenblatt discusses treatment options for patients with NORSE [New-onset refractory status epilepticus]. This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.

Dr. Adam S. Greenblatt discusses and defines New-Onset Refractory Status Epilepticus (NORSE). This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.

In this episode, I sit down with Jimmy Pruitt of the PharmSoHard podcast and talk about my favorite; status epilepticus. Support the showFind ER-Rx: - On Instagram: @ERRxPodcast - On the website: errxpodcast.com - On YouTube Disclaimer: The information contained within the ER-Rx podcast episodes, errxpodcast.com, and the @errxpodcast Instagram page is for informational/ educational purposes only, is not meant to replace professional medical judgement, and does not constitute a provider-patient relationship between you and the authors. Information contained herein may be accidentally inaccurate, incomplete, or outdated, and users are to use caution, seek medical advice from a licensed physician, and consult available resources prior to any medical decision making. The contributors of the ER-Rx podcast are not affiliated with, nor do they speak on behalf of, any medical institutions, educational facilities, or other healthcare programs.

The post Episode 97. Straight Outta Control: Managing Status Epilepticus Like a Boss with Adis Keric appeared first on The Pharm So Hard Podcast.

MedLink Neurology Podcast is delighted to feature selected episodes from BrainWaves, courtesy of James E Siegler MD, its originator and host. BrainWaves is an academic audio podcast whose mission is to educate medical providers through clinical cases and topical reviews in neurology, medicine, and the humanities, and episodes originally aired from 2016 to 2021. Originally released: July 18, 2017 It may come as a surprise to you, but patients who seize...will seize. And in this week's episode, we talk about the fundamentals in working up a patient who presents with status epilepticus. So SEIZE the opportunity to learn from Dr. Chloe Hill as she navigates us through this week's Teaching through Clinical Cases. BrainWaves podcasts and online content are intended for medical education only and should not be used to guide medical decision-making in routine clinical practice. The content in this episode was vetted and approved by Chloe Hill. REFERENCES  Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia 2002;43(2):146-53. PMID 11903460 Mayer SA, Claassen J, Lokin J, Mendelsohn F, Dennis LJ, Fitzsimmons BF. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol 2002;59(2):205-10. PMID 11843690 Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998;339(12):792-8. PMID 9738086  We believe that the principles expressed or implied in the podcast remain valid, but certain details may be superseded by evolving knowledge since the episode's original release date.

In this EM Quick Hits podcast: Justin Hensley and Aaron Billin on Wilderness Medicine, Elisha Targonsky on Bowel Prep Hyponatremia, Brit Long on Non-Convulsive Status Epilepticus, Andrew Petrosoniak on Morel Lavallee Lesions, Jesse McLaren on Pacemaker ECGs and Matt Poyner on paying off loans vs investing... The post EM Quick Hits 46 – Wilderness Medicine, Bowel Prep Hyponatremia, Non-Convulsive Status Epilepticus, Morel Lavallee Lesions, Pacemaker ECGs, Loans vs Investing appeared first on Emergency Medicine Cases.

Status Epilepticus is one of the most common pediatric neurologic emergencies and requires prompt, targeted treatment to reduce patient morbidity and mortality. On this podcast, Pediatric Critical Care Physician, Dr. Renuka Mehta, Pediatric Resident Physician, Dr. Yvonne Ibe, and medical student, Emily Austin will discuss management for status epilepticus and rapid interventions that can be potentially lifesaving—because in seizure management, time is brain.  FREE CME Credit (requires sign-in):  Link Coming Soon! Thank you for listening to this episode from the Department of Pediatrics at the Medical College of Georgia. An additional thanks to Dr. Lorna Bell, Dr. George Hsu, and Dr. Rebecca Yang who provided editing and peer review of today's discussion. If you have any comments, suggestions, or feedback- you can email us at mcgpediatricpodcast@augusta.edu Remember that all content during this episode is intended for educational purposes only. It should not be used as medical advice to diagnose or treat any particular patient. Clinical vignette cases presented are based on hypothetical patient scenarios. Thank you for your support! References: Alldredge, B. K., Gelb, A. M., Isaacs, S. M., Corry, M. D., Allen, F., Ulrich, S., Gottwald, M. D., O'Neil, N., Neuhaus, J. M., Segal, M. R., & Lowenstein, D. H. (2001). A Comparison of Lorazepam, Diazepam, and Placebo for the Treatment of Out-of-Hospital Status Epilepticus. New England Journal of Medicine, 345(9), 631–637. https://doi.org/10.1056/NEJMoa002141  Chamberlain, J. M., Kapur, J., Shinnar, S., Elm, J., Holsti, M., Babcock, L., Rogers, A., Barsan, W., Cloyd, J., Lowenstein, D., Bleck, T. P., Conwit, R., Meinzer, C., Cock, H., Fountain, N. B., Underwood, E., Connor, J. T., Silbergleit, R., Neurological Emergencies Treatment Trials, & Pediatric Emergency Care Applied Research Network investigators. (2020). Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. Lancet (London, England), 395(10231), 1217–1224. https://doi.org/10.1016/S0140-6736(20)30611-5  Chamberlain, J. M., Okada, P., Holsti, M., Mahajan, P., Brown, K. M., Vance, C., Gonzalez, V., Lichenstein, R., Stanley, R., Brousseau, D. C., Grubenhoff, J., Zemek, R., Johnson, D. W., Clemons, T. E., & Baren, J. (2014). Lorazepam vs Diazepam for Pediatric Status Epilepticus: A Randomized Clinical Trial. JAMA, 311(16), 1652. https://doi.org/10.1001/jama.2014.2625  Chen, J., Xie, L., Hu, Y., Lan, X., & Jiang, L. (2018). Nonconvulsive status epilepticus after cessation of convulsive status epilepticus in pediatric intensive care unit patients. Epilepsy & Behavior: E&B, 82, 68–73. https://doi.org/10.1016/j.yebeh.2018.02.008  Fine, A., & Wirrell, E. C. (2020). Seizures in Children. Pediatrics in Review, 41(7), 321–347. https://doi.org/10.1542/pir.2019-0134  Glauser, T., Shinnar, S., Gloss, D., Alldredge, B., Arya, R., Bainbridge, J., Bare, M., Bleck, T., Dodson, W. E., Garrity, L., Jagoda, A., Lowenstein, D., Pellock, J., Riviello, J., Sloan, E., & Treiman, D. M. (2016). Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Currents, 16(1), 48–61. https://doi.org/10.5698/1535-7597-16.1.48  Hanhan, U. A., Fiallos, M. R., & Orlowski, J. P. (2001). Status epilepticus. Pediatric Clinics of North America, 48(3), 683–694. https://doi.org/10.1016/s0031-3955(05)70334-5  Kapur, J., Elm, J., Chamberlain, J. M., Barsan, W., Cloyd, J., Lowenstein, D., Shinnar, S., Conwit, R., Meinzer, C., Cock, H., Fountain, N., Connor, J. T., Silbergleit, R., & NETT and PECARN Investigators. (2019). Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. The New England Journal of Medicine, 381(22), 2103–2113. https://doi.org/10.1056/NEJMoa1905795  Lyttle, M. D., Rainford, N. E. A., Gamble, C., Messahel, S., Humphreys, A., Hickey, H., Woolfall, K., Roper, L., Noblet, J., Lee, E. D., Potter, S., Tate, P., Iyer, A., Evans, V., Appleton, R. E., Pereira, M., Hardwick, S., Messahel, S., Noblet, J., … Hobden, G. (2019). Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. The Lancet, 393(10186), 2125–2134. https://doi.org/10.1016/S0140-6736(19)30724-X  Raspall‐Chaure, M., Chin, R. F. M., Neville, B. G., Bedford, H., & Scott, R. C. (2007). The Epidemiology of Convulsive Status Epilepticus in Children: A Critical Review. Epilepsia, 48(9), 1652–1663. https://doi.org/https://doi.org/10.1111/j.1528-1167.2007.01175.x  Riviello, J. J., Ashwal, S., Hirtz, D., Glauser, T., Ballaban-Gil, K., Kelley, K., Morton, L. D., Phillips, S., Sloan, E., Shinnar, S., American Academy of Neurology Subcommittee, & Practice Committee of the Child Neurology Society. (2006). Practice parameter: diagnostic assessment of the child with status epilepticus (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology, 67(9), 1542–1550. https://doi.org/10.1212/01.wnl.0000243197.05519.3d  Sánchez Fernández, I., Abend, N. S., Agadi, S., An, S., Arya, R., Brenton, J. N., Carpenter, J. L., Chapman, K. E., Gaillard, W. D., Glauser, T. A., Goodkin, H. P., Kapur, K., Mikati, M. A., Peariso, K., Ream, M., Riviello, J., Tasker, R. C., & Loddenkemper, T. (2015). Time from convulsive status epilepticus onset to anticonvulsant administration in children. Neurology, 84(23), 2304–2311. https://doi.org/10.1212/WNL.0000000000001673  Trinka, E., Cock, H., Hesdorffer, D., Rossetti, A. O., Scheffer, I. E., Shinnar, S., Shorvon, S., & Lowenstein, D. H. (2015). A definition and classification of status epilepticus--Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia, 56(10), 1515–1523. https://doi.org/10.1111/epi.13121  Welch, R. D., Nicholas, K., Durkalski-Mauldin, V. L., Lowenstein, D. H., Conwit, R., Mahajan, P. V., Lewandowski, C., Silbergleit, R., & Neurological Emergencies Treatment Trials (NETT) Network Investigators. (2015). Intramuscular midazolam versus intravenous lorazepam for the prehospital treatment of status epilepticus in the pediatric population. Epilepsia, 56(2), 254–262. https://doi.org/10.1111/epi.12905 

Status epilepticus is a life-threatening emergency. However, there are different forms of status epilepticus: focal to bilateral tonic-clonic status epilepticus and focal status epilepticus. Focal status epilepticus may have prominent motor symptoms, often with impaired awareness, or may be nonconvulsive. The implications of this are important: the treatment of focal to bilateral tonic-clonic seizures requires immediate action. Evidence for first-line therapy is clear that benzodiazepines should be administered in adequate doses we will review those studies. New evidence for second-line treatment has emerged, as well. In those with focal status epilepticus, urgent treatment is still indicated but the approach is more nuanced and less likely to require an escalation to third-line agents, such as anesthetics. We review these concepts and provide some guidance for clinical practice.

Dr Gail Davison and Dr Ben Rafferty debate whether children with status epilepticus should be extubated in the district general hospital. This talk is part of the Paediatric Emergencies 2022 event. To get your CME certificate for listening to this podcast please visit https://www.paediatricemergencies.com/conference/paediatric-emergencies-2022/

Join David and Dr. Zach Daniels again as they discuss status epilepticus!

Dr. Ingo Helbig discusses the use of ketamine for the management of neonatal and pediatric refractory status epilepticus. Show references: https://n.neurology.org/content/99/12/e1227 This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.

Dr. Halley Alexander talks with Dr. Ingo Helbig about the use of ketamine for management of neonatal and pediatric refractory status epilepticus. Read the full article in Neurology. This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.

National guidelines for the management of seizures recommend midazolam 10 mg IM as first line therapy. The big question is how often EMS follows this guideline or how well that guideline matches up to real world use. Dr. Jarvis makes a road trip to ESO headquarters to discuss this paper using the ESO research dataset with newly minted Texan Mike Verkest and special guest Dr Remle Crowe. We go deep on the very interesting methodology used in this paper as we get our nerd on! Citation: Guterman EL, Sporer KA, Newman TB, et al. Real-World Midazolam Use and Outcomes With Out-of-Hospital Treatment of Status Epilepticus in the United States. Annals of Emergency Medicine. Published online August 2022. doi:10.1016/j.annemergmed.2022.05.024See omnystudio.com/listener for privacy information.

Show notes at pharmacyjoe.com/episode733. In this episode, I'll discuss how a pharmacist can ensure the best possible outcomes for status epilepticus. The post 733: How a pharmacist can ensure the best possible outcomes for status epilepticus appeared first on Pharmacy Joe.

Show notes at pharmacyjoe.com/episode733. In this episode, I ll discuss how a pharmacist can ensure the best possible outcomes for status epilepticus. The post 733: How a pharmacist can ensure the best possible outcomes for status epilepticus appeared first on Pharmacy Joe.

Status epilepticus is a serious medical emergency. Fortunately, it is relatively rare but when it does occur it can cause a range of serious complications including focal neurological deficits, cognitive dysfunction, and behavioural problems. So it is important that we get the diagnosis and management of this condition right. In this BMJ Best Practice podcast on status epilepticus, Kieran Walsh talks to Dr. Rajiv Mohanraj, Consultant Neurologist and Honorary Senior Lecturer at the Manchester Centre for Clinical Neurosciences - The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner's judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.

Show notes at pharmacyjoe.com/episode729. In this episode, I'll discuss what works best for toxin-related status epilepticus. The post 729: What Works Best for Toxin-Related Status Epilepticus? appeared first on Pharmacy Joe.

Show notes at pharmacyjoe.com/episode729. In this episode, I ll discuss what works best for toxin-related status epilepticus. The post 729: What Works Best for Toxin-Related Status Epilepticus? appeared first on Pharmacy Joe.

No episódio de hoje do Check-up Semanal, o editor-chefe médico do Portal PEBMED, Ronaldo Gismondi, destaca os principais resumos da semana na medicina. Fique atualizado sobre: levetiracetam no status epilepticus, comparação entre tipos de hidratantes na dermatite atópica infantil e tomografia no diagnóstico de hérnia interna após cirurgia bariátrica. Encerrando o podcast, saiba mais sobre hipotireoidismo na gestação sobre e síndrome de Wellens. Aperta o play e ouça agora o episódio.

In this episode we are joined by Professor Hannah Cock to discuss the topic of Status Epilepticus

Someone who has persistent seizures that last more than 24 hours, despite treatment, is in super refractory status epilepticus, or SRSE. The condition is rare, but often results in death or disability.Bringing someone out of SRSE usually involves treatment with anti-seizure medications and anesthetics, but other therapies are beginning to gain attention. One of those therapies is the ketogenic diet. This high-fat diet has been used to treat some cases of epilepsy for more than 100 years.A recent paper in Neurology Clinical Practice offers practical considerations for the use of the ketogenic diet in patients with super-refractory status epilepticus. ILAE spoke with two of the paper's authors – dietitian Neha Kaul and epileptologist Joshua Laing.For guidance on providing the ketogenic diet, contact Neha Kaul.Read the paper: Practical Considerations for Ketogenic Diet in Adults With Super-Refractory Status Epilepticus | Neurology Clinical Practice More about the ketogenic diet as epilepsy treatment (ILAE Epigraph article).Sharp Waves content is meant for informational purposes only and not as medical or clinical advice. The International League Against Epilepsy is the world's preeminent association of health professionals and scientists, working toward a world where no person's life is limited by epilepsy. Visit us on Facebook, Twitter, and Instagram. Support the showSharp Waves episodes are meant for informational purposes only, and not as clinical or medical advice.The International League Against Epilepsy is the world's preeminent association of health professionals and scientists, working toward a world where no person's life is limited by epilepsy. Visit us on Facebook, Twitter, and Instagram.

Status Epilepticus with Dr. Manette Ness-Cochinwala and Dr. Anuj Jayakar About our guests: Dr. Manette Ness-Cochinwala is a Pediatric Intensivist at Rutgers Robert Wood Johnson in NJ. Dr. Ness-Cochinwala completed her Pediatric Critical Care Fellowship at Nicklaus Children's Hospital in Miami, Florida. She is interested in medical education and data science research. Dr. Anuj Jayakar is a neurointensivist and the Director of Neurocritical Care at Nicklaus Children's Hospital. Dr Jayakar completed his pediatric residency at Nicklaus Children's Hospital and his neurology residency and epilepsy fellowship at Boston Children's.How to support PedsCrit?Please share, like, rate and review on Apple Podcasts or Spotify!Donations appreciated @PedsCrit on Venmo --100% of all funds will go to supporting the show to keep this project going.Learning Objectives: After listening to this podcast, learners should be able to:Define status epilepticus, its pathophysiology and its complications. Know the initial and advanced treatment strategies for status epilepticus. Define which patients are at higher risk of nonconvulsive status epilepticus and require continuous EEG monitoring.Thank you for listening to this episode of PedsCrit. Please remember that all content during this episode is intended for educational and entertainment purposes only. It should not be used as medical advice. The views expressed during this episode by hosts and our guests are their own and do not reflect the official position of their institutions. If you have any comments, suggestions, or feedback-you can email us at pedscritpodcast@gmail.com.  You can also visit @critpeds on twitter and @pedscrit on instagram for real time show updates. Support the show

In this episode, our host, David Clifford, walks through a Status Epilepticus event he experienced. When a seizure lasts more than five minutes, it becomes a true emergency situation because there is a good chance that the seizure will not end by itself naturally. Additionally, if a person with Epilepsy […] The post 012: Status Epilepticus appeared first on Brain Ablaze.

Freddy Frost, research fellow in cystic fibrosis in Liverpool, and Alex Pickard, trainee in acute and emergency medicine in South London, are back on The Rounds Table this week. They are covering treatment of paediatric convulsive status epilepticus and the effect of aclidinium bromide on cardiovascular events and exacerbations in patients with chronic obstructive pulmonary disease ...The post A Total Eclipse: Treatment of Status Epilepticus and Aclidinium Bromide in COPD appeared first on Healthy Debate.

Introduction Simple seizure Seizure ends in 5 minutes OR Patient has a 2nd seizure before waking up from 1st Initiate status epilepticus pathway Approach to Status Epilepticus Step 1: Give a benzodiazepine Lorazepam (IV) Diazepam (IV or PR) Midazolam […]